Primecap Management Co/CA filed an amendment to Schedule 13G reporting beneficial ownership of 15,795,383 shares of BioMarin Pharmaceutical Inc. common stock, equal to 8.24% of the class. The filing shows Primecap has sole voting power over 15,087,400 shares and sole dispositive power over 15,795,383 shares. The statement is for CUSIP 09061G101 and designates the security class as common stock. Item 10 certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing is dated as an event on 06/30/2025 and signed on 08/13/2025.
BioMarin Pharmaceutical Inc. announced that Erin Burkhart, Group Vice President and Chief Accounting Officer, notified the company of her voluntary resignation effective September 2, 2025. The company will search for a successor and, if none is appointed by the effective date, Brian Mueller, Executive Vice President and Chief Financial Officer, will serve as principal accounting officer in addition to his CFO duties. The filing states Ms. Burkhart's departure is not due to any disagreement with the company. Mr. Mueller will not receive additional compensation for performing the accounting officer role and has no reportable related-party transactions.
BioMarin Pharmaceutical Inc. (BMRN) – Form 4
On 08/01/2025, director Ian T. Clark was awarded 7,000 restricted stock units (RSUs) of BioMarin common stock, recorded with transaction code “A” (acquisition). Because RSUs are granted by the company, the stated price is $0.00 and no open-market cash outlay occurred. Following the grant, Clark’s direct beneficial ownership stands at 7,000 shares; no indirect holdings or derivative positions were reported. The filing contains no sales, options, or additional equity instruments.
The transaction represents routine director equity compensation rather than an opportunistic purchase, but it modestly increases insider alignment with shareholders. No earnings data, guidance changes, or other material corporate events accompany this filing.
Filing: Form S-8 filed by BioMarin Pharmaceutical Inc. (BMRN) on August 5, 2025 to register additional shares under an employee plan.
Key action: The registrant amended the BioMarin 2017 Equity Incentive Plan (as amended April 1, 2025) and registered 8,000,000 additional shares of Common Stock for issuance under the 2017 Plan.
Other facts: The statement incorporates by reference prior S-8 filings (File Nos. 333-218695, 333-234231, 333-262824, 333-275273); exhibits include the Restated Certificate of Incorporation, Amended and Restated Bylaws, legal opinion of Cooley LLP, consent of KPMG LLP, the amended 2017 Plan (Exhibit 99.1), and a filing fee table. The filing is signed by executive officers and directors on August 5, 2025.
Q2 2025 highlights: BioMarin (BMRN) generated total revenue of $825.4 million, up 16% YoY, led by VOXZOGO (+20%) and VIMIZIM (+21%). Cost of sales grew in line with volume, while R&D (-12%) and SG&A (-12%) fell, expanding operating income to $276.9 million versus $120.5 million last year. Net income more than doubled to $240.5 million; diluted EPS rose to $1.23 from $0.55.
Margins & cash: Gross margin remained about 81.5%; operating margin widened to 33.5% (19.0% prior year). Operating cash flow climbed 117% to $359.7 million, lifting cash and equivalents to $1.21 billion. Convertible debt is unchanged at $600 million, leaving net leverage very low. Retained earnings swung to a $232 million surplus from a $(195) million deficit at year-end.
Product mix Q2 2025:
- VOXZOGO $221.4 m
- VIMIZIM $215.4 m
- NAGLAZYME $128.9 m
- PALYNZIQ $105.9 m
- ALDURAZYME $56.4 m
- BRINEURA $48.7 m
- KUVAN $27.0 m (generic erosion)
- ROCTAVIAN $9.2 m
Balance-sheet notes: Inventory increased 9% to $1.34 billion; AOCI turned to a $(44.6) million loss mainly from FX hedge marks. Three customers represent 38% of net product revenue.
Events after quarter-end: Closed $270 million all-cash acquisition of Inozyme Pharma, adding late-stage enzyme therapy BMN-401; assessing impact of newly enacted U.S. OBBB tax law.